Literature DB >> 19564254

Continued impact of pneumococcal conjugate vaccine on carriage in young children.

Susan S Huang1, Virginia L Hinrichsen, Abbie E Stevenson, Sheryl L Rifas-Shiman, Ken Kleinman, Stephen I Pelton, Marc Lipsitch, William P Hanage, Grace M Lee, Jonathan A Finkelstein.   

Abstract

OBJECTIVES: The goals were to assess serial changes in Streptococcus pneumoniae serotypes and antibiotic resistance in young children and to evaluate whether risk factors for carriage have been altered by heptavalent pneumococcal conjugate vaccine (PCV7).
METHODS: Nasopharyngeal specimens and questionnaire/medical record data were obtained from children 3 months to <7 years of age in primary care practices in 16 Massachusetts communities during the winter seasons of 2000-2001 and 2003-2004 and in 8 communities in 2006-2007. Antimicrobial susceptibility testing and serotyping were performed with S pneumoniae isolates.
RESULTS: We collected 678, 988, and 972 specimens during the sampling periods in 2000-2001, 2003-2004, and 2006-2007, respectively. Carriage of non-PCV7 serotypes increased from 15% to 19% and 29% (P < .001), with vaccine serotypes decreasing to 3% of carried serotypes in 2006-2007. The relative contribution of several non-PCV7 serotypes, including 19A, 35B, and 23A, increased across sampling periods. By 2007, commonly carried serotypes included 19A (16%), 6A (12%), 15B/C (11%), 35B (9%), and 11A (8%), and high-prevalence serotypes seemed to have greater proportions of penicillin nonsusceptibility. In multivariate models, common predictors of pneumococcal carriage, such as child care attendance, upper respiratory tract infection, and the presence of young siblings, persisted.
CONCLUSIONS: The virtual disappearance of vaccine serotypes in S pneumoniae carriage has occurred in young children, with rapid replacement with penicillin-nonsusceptible nonvaccine serotypes, particularly 19A and 35B. Except for the age group at highest risk, previous predictors of carriage, such as child care attendance and the presence of young siblings, have not been changed by the vaccine.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19564254      PMCID: PMC2782668          DOI: 10.1542/peds.2008-3099

Source DB:  PubMed          Journal:  Pediatrics        ISSN: 0031-4005            Impact factor:   7.124


  40 in total

1.  Evolving microbiology and molecular epidemiology of acute otitis media in the pneumococcal conjugate vaccine era.

Authors:  Michael E Pichichero; Janet R Casey
Journal:  Pediatr Infect Dis J       Date:  2007-10       Impact factor: 2.129

2.  Population-based surveillance for childhood invasive pneumococcal disease in the era of conjugate vaccine.

Authors:  Katherine Hsu; Stephen Pelton; Sudharani Karumuri; Dawn Heisey-Grove; Jerome Klein
Journal:  Pediatr Infect Dis J       Date:  2005-01       Impact factor: 2.129

3.  Immunogenicity and impact on nasopharyngeal carriage of a nonavalent pneumococcal conjugate vaccine.

Authors:  N Mbelle; R E Huebner; A D Wasas; A Kimura; I Chang; K P Klugman
Journal:  J Infect Dis       Date:  1999-10       Impact factor: 5.226

4.  Reduction of nasopharyngeal carriage of pneumococci during the second year of life by a heptavalent conjugate pneumococcal vaccine.

Authors:  R Dagan; R Melamed; M Muallem; L Piglansky; D Greenberg; O Abramson; P M Mendelman; N Bohidar; P Yagupsky
Journal:  J Infect Dis       Date:  1996-12       Impact factor: 5.226

5.  Postlicensure surveillance for pneumococcal invasive disease after use of heptavalent pneumococcal conjugate vaccine in Northern California Kaiser Permanente.

Authors:  Steven Black; Henry Shinefield; Roger Baxter; Robert Austrian; Laura Bracken; John Hansen; Edwin Lewis; Bruce Fireman
Journal:  Pediatr Infect Dis J       Date:  2004-06       Impact factor: 2.129

6.  Emergence of a multiresistant serotype 19A pneumococcal strain not included in the 7-valent conjugate vaccine as an otopathogen in children.

Authors:  Michael E Pichichero; Janet R Casey
Journal:  JAMA       Date:  2007-10-17       Impact factor: 56.272

7.  Emergence of antimicrobial-resistant serotype 19A Streptococcus pneumoniae--Massachusetts, 2001-2006.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2007-10-19       Impact factor: 17.586

8.  Antibiotic-resistant Streptococcus pneumoniae in the heptavalent pneumococcal conjugate vaccine era: predictors of carriage in a multicommunity sample.

Authors:  Jonathan A Finkelstein; Susan S Huang; James Daniel; Sheryl L Rifas-Shiman; Ken Kleinman; Donald Goldmann; Stephen I Pelton; Alfred DeMaria; Richard Platt
Journal:  Pediatrics       Date:  2003-10       Impact factor: 7.124

9.  Seven valent pneumococcal conjugate vaccine immunization in two Boston communities: changes in serotypes and antimicrobial susceptibility among Streptococcus pneumoniae isolates.

Authors:  Stephen I Pelton; Anita M Loughlin; Colin D Marchant
Journal:  Pediatr Infect Dis J       Date:  2004-11       Impact factor: 2.129

10.  Vaccine escape recombinants emerge after pneumococcal vaccination in the United States.

Authors:  Angela B Brueggemann; Rekha Pai; Derrick W Crook; Bernard Beall
Journal:  PLoS Pathog       Date:  2007-11       Impact factor: 6.823

View more
  134 in total

1.  Unveiling the burden of influenza-associated pneumococcal pneumonia.

Authors:  Carlos G Grijalva; Marie R Griffin
Journal:  J Infect Dis       Date:  2011-12-07       Impact factor: 5.226

2.  Probing ligand-binding pockets of the mevalonate pathway enzymes from Streptococcus pneumoniae.

Authors:  Scott T Lefurgy; Sofia B Rodriguez; Chan Sun Park; Sean Cahill; Richard B Silverman; Thomas S Leyh
Journal:  J Biol Chem       Date:  2010-04-19       Impact factor: 5.157

3.  Increasing incidence of Streptococcus pneumoniae serotype 19A and emergence of two vaccine escape recombinant ST695 strains in Liguria, Italy, 7 years after implementation of the 7-valent conjugated vaccine.

Authors:  Filippo Ansaldi; Paola Canepa; Daniela de Florentiis; Roberto Bandettini; Paolo Durando; Giancarlo Icardi
Journal:  Clin Vaccine Immunol       Date:  2010-12-22

Review 4.  Regulation of bacterial trafficking in the nasopharynx.

Authors:  Stephen I Pelton
Journal:  Paediatr Respir Rev       Date:  2012-05-02       Impact factor: 2.726

5.  A new pneumococcal serotype, 11E, has a variably inactivated wcjE gene.

Authors:  Juan J Calix; Moon H Nahm
Journal:  J Infect Dis       Date:  2010-07-01       Impact factor: 5.226

6.  Conjugation of PspA4Pro with Capsular Streptococcus pneumoniae Polysaccharide Serotype 14 Does Not Reduce the Induction of Cross-Reactive Antibodies.

Authors:  Míriam A da Silva; Thiago R Converso; Viviane M Gonçalves; Luciana C C Leite; Martha M Tanizaki; Giovana C Barazzone
Journal:  Clin Vaccine Immunol       Date:  2017-08-04

7.  Evidence that pneumococcal serotype replacement in Massachusetts following conjugate vaccination is now complete.

Authors:  William P Hanage; Jonathan A Finkelstein; Susan S Huang; Stephen I Pelton; Abbie E Stevenson; Ken Kleinman; Virginia L Hinrichsen; Christophe Fraser
Journal:  Epidemics       Date:  2010-06       Impact factor: 4.396

8.  Nasopharyngeal carriage of Streptococcus pneumoniae in healthy Turkish children after the addition of PCV7 to the national vaccine schedule.

Authors:  Halil Ozdemir; Ergin Ciftçi; Rıza Durmaz; Haluk Güriz; Ahmet Derya Aysev; Adem Karbuz; Refik Gökdemir; Bülent Acar; Selin Nar Ötgün; Mustafa Ertek; Serdal Kenan Köse; Erdal Ince
Journal:  Eur J Pediatr       Date:  2013-09-18       Impact factor: 3.183

9.  Mevalonate analogues as substrates of enzymes in the isoprenoid biosynthetic pathway of Streptococcus pneumoniae.

Authors:  Takashi Kudoh; Chan Sun Park; Scott T Lefurgy; Meihao Sun; Theodore Michels; Thomas S Leyh; Richard B Silverman
Journal:  Bioorg Med Chem       Date:  2009-12-24       Impact factor: 3.641

Review 10.  Panel 6: Vaccines.

Authors:  Stephen I Pelton; Melinda M Pettigrew; Stephen J Barenkamp; Fabrice Godfroid; Carlos G Grijalva; Amanda Leach; Janak Patel; Timothy F Murphy; Sanja Selak; Lauren O Bakaletz
Journal:  Otolaryngol Head Neck Surg       Date:  2013-04       Impact factor: 3.497

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.